Concepts (210)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stroke | 38 | 2022 | 2163 | 6.090 |
Why?
|
| Thrombectomy | 20 | 2022 | 238 | 4.610 |
Why?
|
| Tissue Plasminogen Activator | 11 | 2021 | 296 | 3.540 |
Why?
|
| Fibrinolytic Agents | 12 | 2021 | 377 | 3.120 |
Why?
|
| Telemedicine | 12 | 2021 | 700 | 2.440 |
Why?
|
| Brain Ischemia | 12 | 2022 | 665 | 2.420 |
Why?
|
| Pandemics | 6 | 2021 | 352 | 2.400 |
Why?
|
| Intracranial Arteriosclerosis | 8 | 2021 | 134 | 2.230 |
Why?
|
| Endovascular Procedures | 11 | 2022 | 366 | 2.080 |
Why?
|
| Coronavirus Infections | 4 | 2020 | 143 | 1.890 |
Why?
|
| Pneumonia, Viral | 4 | 2020 | 154 | 1.880 |
Why?
|
| Time-to-Treatment | 7 | 2021 | 117 | 1.780 |
Why?
|
| Thrombolytic Therapy | 10 | 2021 | 233 | 1.530 |
Why?
|
| Treatment Outcome | 30 | 2022 | 7029 | 1.090 |
Why?
|
| Neurosurgery | 3 | 2022 | 42 | 1.060 |
Why?
|
| Aged | 33 | 2022 | 14862 | 0.990 |
Why?
|
| Stents | 12 | 2021 | 657 | 0.980 |
Why?
|
| Aged, 80 and over | 20 | 2022 | 4848 | 0.940 |
Why?
|
| Intracranial Aneurysm | 3 | 2021 | 87 | 0.940 |
Why?
|
| Space Flight | 2 | 2022 | 40 | 0.940 |
Why?
|
| Carotid Artery Diseases | 2 | 2021 | 83 | 0.890 |
Why?
|
| Neurology | 2 | 2020 | 43 | 0.850 |
Why?
|
| Humans | 62 | 2022 | 68618 | 0.850 |
Why?
|
| Ischemic Attack, Transient | 2 | 2021 | 167 | 0.840 |
Why?
|
| Cerebral Hemorrhage | 3 | 2019 | 198 | 0.840 |
Why?
|
| Middle Aged | 32 | 2022 | 21147 | 0.790 |
Why?
|
| Remote Consultation | 1 | 2021 | 50 | 0.740 |
Why?
|
| Transportation of Patients | 1 | 2021 | 46 | 0.740 |
Why?
|
| Embolization, Therapeutic | 5 | 2022 | 150 | 0.730 |
Why?
|
| Healthcare Disparities | 3 | 2021 | 378 | 0.720 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 18 | 0.710 |
Why?
|
| Personal Protective Equipment | 1 | 2020 | 27 | 0.710 |
Why?
|
| Male | 36 | 2022 | 37321 | 0.700 |
Why?
|
| Triage | 1 | 2021 | 109 | 0.690 |
Why?
|
| Female | 36 | 2022 | 38074 | 0.690 |
Why?
|
| Infection Control | 1 | 2020 | 101 | 0.660 |
Why?
|
| Retrospective Studies | 21 | 2022 | 7277 | 0.650 |
Why?
|
| Emergency Medical Services | 1 | 2021 | 225 | 0.620 |
Why?
|
| Phantoms, Imaging | 1 | 2019 | 189 | 0.610 |
Why?
|
| Atherosclerosis | 2 | 2017 | 204 | 0.600 |
Why?
|
| Postprandial Period | 1 | 2017 | 21 | 0.570 |
Why?
|
| Prospective Studies | 9 | 2022 | 3705 | 0.570 |
Why?
|
| Time Factors | 12 | 2021 | 4655 | 0.550 |
Why?
|
| Hospitals, Rural | 1 | 2017 | 43 | 0.550 |
Why?
|
| Computed Tomography Angiography | 2 | 2019 | 424 | 0.510 |
Why?
|
| Anticonvulsants | 1 | 2016 | 223 | 0.490 |
Why?
|
| Disease Management | 1 | 2016 | 248 | 0.490 |
Why?
|
| Lipoproteins, LDL | 1 | 2017 | 343 | 0.480 |
Why?
|
| Seizures | 1 | 2016 | 279 | 0.470 |
Why?
|
| Epilepsy | 1 | 2016 | 336 | 0.420 |
Why?
|
| Cerebral Angiography | 4 | 2020 | 151 | 0.410 |
Why?
|
| Hematoma, Subdural, Chronic | 2 | 2022 | 9 | 0.400 |
Why?
|
| Astronauts | 2 | 2022 | 20 | 0.390 |
Why?
|
| Administration, Intravenous | 4 | 2019 | 89 | 0.390 |
Why?
|
| Workflow | 2 | 2020 | 100 | 0.340 |
Why?
|
| Benchmarking | 2 | 2020 | 91 | 0.340 |
Why?
|
| Radial Artery | 2 | 2020 | 43 | 0.330 |
Why?
|
| Cerebrovascular Disorders | 2 | 2020 | 182 | 0.330 |
Why?
|
| Hospital Mortality | 2 | 2021 | 384 | 0.320 |
Why?
|
| Catheters | 3 | 2022 | 39 | 0.290 |
Why?
|
| Adult | 11 | 2021 | 21403 | 0.280 |
Why?
|
| Angioplasty | 2 | 2019 | 118 | 0.280 |
Why?
|
| Risk Factors | 10 | 2022 | 5731 | 0.280 |
Why?
|
| Carotid Artery, Internal | 3 | 2021 | 85 | 0.280 |
Why?
|
| United States | 7 | 2021 | 7367 | 0.280 |
Why?
|
| South Carolina | 5 | 2020 | 2752 | 0.270 |
Why?
|
| Secondary Prevention | 2 | 2017 | 291 | 0.260 |
Why?
|
| Registries | 4 | 2021 | 733 | 0.260 |
Why?
|
| Intracranial Hypertension | 2 | 2022 | 53 | 0.250 |
Why?
|
| Socioeconomic Factors | 2 | 2018 | 955 | 0.250 |
Why?
|
| Blood Pressure | 3 | 2019 | 1451 | 0.240 |
Why?
|
| Antibodies, Antiphospholipid | 2 | 2022 | 29 | 0.240 |
Why?
|
| Risk Assessment | 5 | 2021 | 2007 | 0.240 |
Why?
|
| Feasibility Studies | 3 | 2021 | 652 | 0.240 |
Why?
|
| Cognition | 2 | 2019 | 513 | 0.230 |
Why?
|
| Aneurysm, Ruptured | 2 | 2021 | 40 | 0.220 |
Why?
|
| Recurrence | 4 | 2020 | 948 | 0.220 |
Why?
|
| Central Nervous System Vascular Malformations | 1 | 2022 | 10 | 0.210 |
Why?
|
| Clinical Decision-Making | 2 | 2021 | 109 | 0.210 |
Why?
|
| Intracranial Thrombosis | 1 | 2022 | 14 | 0.210 |
Why?
|
| Betacoronavirus | 2 | 2020 | 116 | 0.200 |
Why?
|
| Anterior Cerebral Artery | 1 | 2021 | 5 | 0.200 |
Why?
|
| Sinus Thrombosis, Intracranial | 1 | 2021 | 20 | 0.200 |
Why?
|
| Georgia | 1 | 2021 | 161 | 0.190 |
Why?
|
| Severity of Illness Index | 4 | 2020 | 1851 | 0.190 |
Why?
|
| Venous Thrombosis | 1 | 2022 | 125 | 0.190 |
Why?
|
| Eye | 1 | 2022 | 89 | 0.190 |
Why?
|
| Syndrome | 1 | 2021 | 255 | 0.190 |
Why?
|
| Cerebral Arterial Diseases | 1 | 2021 | 28 | 0.190 |
Why?
|
| Venous Thromboembolism | 1 | 2022 | 117 | 0.190 |
Why?
|
| Thrombosis | 1 | 2022 | 218 | 0.190 |
Why?
|
| Vision Disorders | 1 | 2021 | 94 | 0.190 |
Why?
|
| Videoconferencing | 1 | 2021 | 43 | 0.190 |
Why?
|
| Internationality | 1 | 2021 | 74 | 0.180 |
Why?
|
| Aneurysm | 1 | 2020 | 53 | 0.180 |
Why?
|
| Angioplasty, Balloon | 1 | 2021 | 110 | 0.180 |
Why?
|
| Infusions, Intravenous | 1 | 2021 | 334 | 0.180 |
Why?
|
| Reperfusion | 1 | 2020 | 78 | 0.180 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2021 | 77 | 0.180 |
Why?
|
| Medicare | 2 | 2019 | 319 | 0.180 |
Why?
|
| Independent Living | 1 | 2020 | 44 | 0.180 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 60 | 0.180 |
Why?
|
| Anesthesia, General | 1 | 2020 | 86 | 0.180 |
Why?
|
| Pilot Projects | 2 | 2021 | 1342 | 0.170 |
Why?
|
| Age Factors | 3 | 2020 | 1864 | 0.170 |
Why?
|
| Intubation, Intratracheal | 1 | 2020 | 99 | 0.170 |
Why?
|
| Certification | 1 | 2020 | 66 | 0.170 |
Why?
|
| Continuity of Patient Care | 1 | 2021 | 170 | 0.170 |
Why?
|
| Femoral Artery | 1 | 2020 | 139 | 0.170 |
Why?
|
| Intraoperative Complications | 1 | 2020 | 129 | 0.170 |
Why?
|
| Patient Transfer | 1 | 2020 | 86 | 0.170 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2019 | 61 | 0.170 |
Why?
|
| Collateral Circulation | 1 | 2019 | 34 | 0.170 |
Why?
|
| Intracranial Arterial Diseases | 1 | 2019 | 15 | 0.170 |
Why?
|
| Southeastern United States | 1 | 2020 | 281 | 0.170 |
Why?
|
| Cerebral Arteries | 1 | 2019 | 50 | 0.170 |
Why?
|
| Air Ambulances | 1 | 2018 | 4 | 0.160 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2019 | 63 | 0.160 |
Why?
|
| Brain Infarction | 1 | 2019 | 54 | 0.160 |
Why?
|
| Linear Models | 1 | 2020 | 521 | 0.160 |
Why?
|
| Amaurosis Fugax | 1 | 2018 | 2 | 0.160 |
Why?
|
| Cohort Studies | 5 | 2022 | 2358 | 0.160 |
Why?
|
| Retinal Artery Occlusion | 1 | 2018 | 7 | 0.160 |
Why?
|
| Mechanical Thrombolysis | 1 | 2018 | 29 | 0.160 |
Why?
|
| Conservative Treatment | 1 | 2018 | 8 | 0.160 |
Why?
|
| Sex Factors | 2 | 2020 | 1266 | 0.160 |
Why?
|
| Observer Variation | 1 | 2019 | 330 | 0.150 |
Why?
|
| Vision, Ocular | 1 | 2018 | 68 | 0.150 |
Why?
|
| Spinal Cord Diseases | 1 | 2018 | 23 | 0.150 |
Why?
|
| Referral and Consultation | 1 | 2020 | 383 | 0.150 |
Why?
|
| Inpatients | 1 | 2019 | 208 | 0.150 |
Why?
|
| Rural Health Services | 1 | 2019 | 101 | 0.150 |
Why?
|
| Injections, Intravenous | 1 | 2018 | 215 | 0.150 |
Why?
|
| Cerebrovascular Circulation | 1 | 2019 | 296 | 0.150 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2019 | 373 | 0.150 |
Why?
|
| Health Services Accessibility | 2 | 2019 | 581 | 0.140 |
Why?
|
| Hemiplegia | 1 | 2017 | 29 | 0.140 |
Why?
|
| Vascular Surgical Procedures | 1 | 2018 | 168 | 0.140 |
Why?
|
| Pregnancy Complications | 1 | 2019 | 286 | 0.140 |
Why?
|
| Risk Reduction Behavior | 1 | 2017 | 174 | 0.140 |
Why?
|
| Light | 1 | 2017 | 152 | 0.130 |
Why?
|
| Brain | 2 | 2017 | 2176 | 0.130 |
Why?
|
| Cardiovascular Agents | 1 | 2016 | 82 | 0.130 |
Why?
|
| Primary Health Care | 1 | 2021 | 703 | 0.130 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2020 | 468 | 0.130 |
Why?
|
| Hemorrhage | 1 | 2018 | 328 | 0.130 |
Why?
|
| American Heart Association | 1 | 2016 | 142 | 0.130 |
Why?
|
| Outpatients | 1 | 2016 | 127 | 0.130 |
Why?
|
| Cognitive Dysfunction | 1 | 2019 | 176 | 0.130 |
Why?
|
| Recovery of Function | 4 | 2021 | 506 | 0.130 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2017 | 507 | 0.130 |
Why?
|
| Patient Compliance | 1 | 2017 | 402 | 0.120 |
Why?
|
| Hospitalization | 1 | 2021 | 978 | 0.120 |
Why?
|
| Electrocardiography | 1 | 2017 | 601 | 0.120 |
Why?
|
| Emergency Service, Hospital | 1 | 2020 | 711 | 0.120 |
Why?
|
| Electroencephalography | 1 | 2016 | 418 | 0.120 |
Why?
|
| Logistic Models | 1 | 2018 | 1420 | 0.120 |
Why?
|
| Cognition Disorders | 1 | 2016 | 342 | 0.110 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 2077 | 0.110 |
Why?
|
| Exercise | 1 | 2019 | 658 | 0.110 |
Why?
|
| Meningeal Arteries | 2 | 2022 | 9 | 0.100 |
Why?
|
| Europe | 2 | 2021 | 196 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2017 | 2223 | 0.090 |
Why?
|
| Basilar Artery | 2 | 2021 | 38 | 0.090 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 3259 | 0.090 |
Why?
|
| Constriction, Pathologic | 2 | 2019 | 236 | 0.070 |
Why?
|
| Databases, Factual | 2 | 2021 | 622 | 0.070 |
Why?
|
| Magnetic Resonance Angiography | 2 | 2019 | 181 | 0.070 |
Why?
|
| Chi-Square Distribution | 2 | 2017 | 546 | 0.070 |
Why?
|
| Pregnancy | 2 | 2022 | 2334 | 0.060 |
Why?
|
| Adolescent | 1 | 2016 | 8912 | 0.060 |
Why?
|
| Cytidine Triphosphate | 1 | 2022 | 3 | 0.050 |
Why?
|
| Perfusion | 1 | 2022 | 131 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2022 | 2324 | 0.050 |
Why?
|
| Asia | 1 | 2021 | 59 | 0.050 |
Why?
|
| Fee-for-Service Plans | 1 | 2021 | 24 | 0.050 |
Why?
|
| North America | 1 | 2021 | 112 | 0.050 |
Why?
|
| Angiography | 1 | 2021 | 194 | 0.050 |
Why?
|
| Thromboembolism | 1 | 2021 | 91 | 0.050 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2021 | 47 | 0.050 |
Why?
|
| Occupational Health | 1 | 2021 | 41 | 0.050 |
Why?
|
| Neurosurgical Procedures | 1 | 2022 | 98 | 0.050 |
Why?
|
| Arteries | 1 | 2021 | 108 | 0.050 |
Why?
|
| Neovascularization, Pathologic | 1 | 2021 | 183 | 0.050 |
Why?
|
| Vertebral Artery | 1 | 2020 | 22 | 0.040 |
Why?
|
| Ventriculoperitoneal Shunt | 1 | 2019 | 16 | 0.040 |
Why?
|
| Middle Cerebral Artery | 1 | 2020 | 57 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 446 | 0.040 |
Why?
|
| Hyperlipidemias | 1 | 2020 | 90 | 0.040 |
Why?
|
| Neurologists | 1 | 2019 | 15 | 0.040 |
Why?
|
| Patient Safety | 1 | 2021 | 202 | 0.040 |
Why?
|
| Drainage | 1 | 2019 | 133 | 0.040 |
Why?
|
| Administrative Claims, Healthcare | 1 | 2018 | 7 | 0.040 |
Why?
|
| After-Hours Care | 1 | 2018 | 17 | 0.040 |
Why?
|
| Blood Pressure Determination | 1 | 2019 | 152 | 0.040 |
Why?
|
| Catheterization | 1 | 2019 | 209 | 0.040 |
Why?
|
| Health Care Costs | 1 | 2021 | 346 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2019 | 294 | 0.040 |
Why?
|
| Disability Evaluation | 1 | 2019 | 298 | 0.040 |
Why?
|
| Telephone | 1 | 2017 | 160 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2018 | 880 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2018 | 1046 | 0.030 |
Why?
|
| Counseling | 1 | 2017 | 280 | 0.030 |
Why?
|
| Prevalence | 1 | 2019 | 1619 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 2016 | 517 | 0.030 |
Why?
|
| Comorbidity | 1 | 2018 | 1426 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2021 | 1615 | 0.030 |
Why?
|
| Child | 1 | 2022 | 6405 | 0.020 |
Why?
|
| Hypertension | 1 | 2019 | 1535 | 0.020 |
Why?
|
| Animals | 1 | 2018 | 20881 | 0.010 |
Why?
|